{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Is a congenital anomaly/birth defect', 'Is an important medical event - Important medical events may not be immediately', 'life-threatening or result in death or hospitalization, but may jeopardize the patient or', 'may require intervention to prevent one of the other serious outcomes listed above', '(eg, intensive treatment in an emergency room or at home for allergic bronchospasm;', 'blood dyscrasias or convulsions that do not result in hospitalization; or development of', 'drug dependency or drug abuse).', 'Hospitalization or death due solely to manifestations consistent with typical progression of', 'underlying malignancy will not be considered an SAE.', '9.3.3.', 'Adverse Events of Special Interest', \"An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's\", 'product or program, for which ongoing monitoring and rapid communication by the investigator', 'to the sponsor can be appropriate. Such an event might warrant further investigation in order to', 'characterize and understand it. Depending on the nature of the event, rapid communication by the', 'trial sponsor to other parties (eg, regulators) might also be warranted (Section 9.4.3).', '9.3.4.', 'Infusion Reactions', 'Infusion reactions are defined as any AE that occurs during the infusion or within 2 hours after the', 'infusion is completed. All infusion reactions must be reported as AEs (see Section 9.4.1) and', 'graded using the grading scale as instructed in Section 9.5.1.', '9.4.', 'Recording and Reporting Adverse Events', '9.4.1.', 'Adverse Events', 'The investigator (or designee) will seek information on AEs at each patient contact, and record all', 'AEs that occur from the time the informed consent is signed until 90 days after the last study', 'treatment, or until the patient commences another anticancer systemic therapy, whichever comes', 'first. After informed consent has been obtained but prior to initiation of study drug, only the', 'following AEs should be reported:', 'SAEs', 'Non-SAEs caused by a protocol-mandated intervention (eg, non-SAEs related to', 'invasive procedures such as biopsies)', 'Other AEs that occur prior to the first treatment should be reported on the medical history CRF.', 'All AEs after initiation of study treatment and until 90 days after the last study treatment,', 'regardless of relationship to study treatment, will be reported on the AE CRF. Additionally, any', 'SAE or other AE of concern that the investigator believes may be related to study treatment and', 'that occurs later than 90 days after last study treatment, or after the patient has commenced another', 'anticancer systemic therapy (whichever comes first) should be reported.', 'Study treatment includes cemiplimab, pemetrexed, gemcitabine, vinorelbine, irinotecan, and', 'topotecan.', 'Regeneron Pharmaceuticals, Inc.', 'Page 89 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Information on follow-up for AEs is provided in Section 9.4.6. Laboratory, vital signs, or ECG', 'abnormalities are to be recorded as AEs as outlined in Section 9.4.5.', '9.4.2.', 'Serious Adverse Events', 'All SAEs, regardless of assessment of causal relationship to study treatment must be reported to', 'the sponsor (or designee) within 24 hours. Refer to the study reference manuals for the procedure', 'to be followed.', 'Information not available at the time of the initial report must be documented in a follow-up report.', 'Substantiating data such as relevant hospital or medical records and diagnostic test reports may', 'also be requested.', 'In the event the investigator is informed of an SAE that occurs after 90 days after the last dose of', 'study treatment, or after the patient commences another anticancer systemic therapy (whichever', 'comes first), only those SAEs or other AEs of concern deemed by the investigator to be related to', 'study treatment will be reported to the sponsor. The investigator should make every effort to', 'obtain follow-up information on the outcome of a treatment-related SAE until the event is', 'considered chronic and/or stable.', '9.4.3.', 'Other Events that Require Accelerated Reporting to Sponsor', 'The following events also require reporting to the sponsor (or designee) within 24 hours of learning', 'of the event:', 'Symptomatic Overdose of Study Drug: Accidental or intentional overdose of at least 2 times', 'the intended dose of study drug within the intended therapeutic window, if', 'associated with an AE.', 'Pregnancy:', 'Although pregnancy is not considered an AE, it is the responsibility of the', 'investigator to report to the sponsor (or designee), within 24 hours of identification,', 'any pregnancy occurring in a female during the study or within 6 months of the last', 'dose of study drug. Any complication of pregnancy affecting a female study patient', 'and/or fetus and/or newborn that meets the SAE criteria must be reported as an', 'SAE. Outcome for all pregnancies should be reported to the sponsor.', 'Adverse Events of Special Interest (applicable to cemiplimab only): All AESI, serious and', 'nonserious, must be reported within 24 hours of identification using the same', 'reporting process as for SAE reporting, per Section 9.4.2. Adverse events of special', 'interest for this study include the following:', 'The following will be considered AESI for this study:', 'Grade >2 infusion related reactions', 'Grade >2 allergic/hypersensitivity reaction', 'Grade >3 irAEs (see Section 8.3.2)', 'An irAE of any grade in a patient previously treated with a PI 3-K inhibitor', 'NOTE (Applicable to cemiplimab only): An irAE can occur shortly after the', 'first dose or several months after the last dose of treatment. All AEs of unknown', 'Regeneron Pharmaceuticals, Inc.', 'Page 90 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}